Sun Pharma Q4 Results Reflect Rising Costs, Moderating Growth Outlook
मुख्य बातें
- •Sun Pharma’s Q4 FY26 revenue grew 11.9% to ₹58,220.1 crore, with net profit also rising, though profit figures were not disclosed.
- •EBITDA margin fell 160 bps YoY to 27.1%, the lowest in eight quarters, due to higher R&D and specialty launch costs.
- •R&D spending hit 6.7% of revenue in Q4 and is expected to remain elevated at 6–7% in FY27 supporting innovation in dermatology, oncology and metabolic therapies.
- •Domestic formulations outperformed industry growth for two years; US formulations declined slightly with recovery expected to be gradual through new launches and capacity expansion.
Sun Pharmaceutical Industries Ltd. delivered double-digit growth in revenue and net profit for the fourth quarter of fiscal year 2026, but its operating profitability came under pressure due to elevated investments in specialty launches and reduced milestone income. The company’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) margin contracted by 160 basis points year-on-year to 27.1%, marking the lowest level in eight quarters.
For the full fiscal year 2026, Sun Pharma posted revenue growth of 11.9%, reaching ₹58,220.1 crore. Net profit also rose significantly during the year, though the company did not disclose specific profit figures in the report. The EBITDA margin decline reflects higher spending on research and development (R&D) and specialty product launches, both of which are expected to continue impacting near-term profitability.
